Primum nan nocere

摘要

We welcome the comments from Stuart Hill (PJ, 10/17 May 2014, p506) providing a counterargument to the concerns initially raised by the UK Clinical Pharmacy Association Respiratory Group about Relvar Ellipta. We would like to address some of his concerns.